Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers.

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...